MedKoo Cat#: 414155 | Name: Nicametate citrate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Nicametate citrate is a vasodilator, which enhances blood flow and oxygen to the brain, aids stroke recovery. It also can use for treating intermittent claudication in certain patients.

Chemical Structure

Nicametate citrate
Nicametate citrate
CAS#1641-74-3 (citrate)

Theoretical Analysis

MedKoo Cat#: 414155

Name: Nicametate citrate

CAS#: 1641-74-3 (citrate)

Chemical Formula: C18H26N2O9

Exact Mass:

Molecular Weight: 414.41

Elemental Analysis: C, 52.17; H, 6.32; N, 6.76; O, 34.75

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Synonym
Nicametate citrate; 5311 C; 53 11 C; 53-11 C; NSC169477; NSC-169477; NSC 169477
IUPAC/Chemical Name
3-Pyridinecarboxylic acid, 2-(diethylamino)ethyl ester, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI)
InChi Key
IABBAGAOMDWOCW-UHFFFAOYSA-N
InChi Code
InChI=1S/C12H18N2O2.C6H8O7/c1-3-14(4-2)8-9-16-12(15)11-6-5-7-13-10-11;7-3(8)1-6(13,5(11)12)2-4(9)10/h5-7,10H,3-4,8-9H2,1-2H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)
SMILES Code
O=C(C1=CC=CN=C1)OCCN(CC)CC.O=C(CC(C(O)=O)(O)CC(O)=O)O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 414.41 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Stankowiak C, Vandecasteele J, Soots G. Utilisation du nicamétate citrate à fortes doses, en chirurgie cardio-vasculaire [Use of citrate nicamétate at high doses in cardiovascular surgery]. Lille Med. 1973 Nov;18(9):1039-42. French. PMID: 4211730. 2: Lee TK, Chan KW, Huang ZS, Ng SK, Lin RT, Po HL, Yuan RY, Lai ML, Chang TW, Yan SH, Deng JC, Liu LH, Lee KY, Lie SK, Sung SM, Hu HH. Effectiveness of low- dose ASA in prevention of secondary ischemic stroke, the ASA Study Group in Taiwan. Thromb Res. 1997 Jul 15;87(2):215-24. doi: 10.1016/s0049-3848(97)00121-7. PMID: 9259112. 3: Langeron P. Essai clinique du nicamétate en pathologie vasclaire [Clinical trial of Nicametate in vascular pathology]. J Sci Med Lille. 1972 Apr;90(4):179-82. French. PMID: 5079565. 4: Fang CC, Yen CJ, Shyu RS, Wu MS, Tsai TJ, Hsieh BS. Pharmacologic agents inhibit rat mesangial cell proliferation and collagen synthesis. J Formos Med Assoc. 1998 Jul;97(7):458-64. PMID: 9700242. 5: Okada F, Kiyota N, Honma M, Ui M. Plasma guanosine 3',5'-monophosphate responses to the cold pressor test in patients with vibration disease. Arch Environ Health. 1983 May-Jun;38(3):144-7. doi: 10.1080/00039896.1983.10543995. PMID: 6307192. 6: Pan SL, Lien IN, Chen TH. Is higher serum total cholesterol level associated with better long-term functional outcomes after noncardioembolic ischemic stroke? Arch Phys Med Rehabil. 2010 Jun;91(6):913-8. doi: 10.1016/j.apmr.2010.02.002. PMID: 20510983. 7: Rousseva S, Petkov VV, Petkov VD, Voronina TA, Nerobkova LN, Ivanova IA, Stoyanova V. Memory effects of the combination of medazepam with nootropic agents. Acta Physiol Pharmacol Bulg. 1988;14(4):27-35. PMID: 2907710. 8: Belozertsev IuA. Zavisimost' deĭstviia psikhostimuliatorov na obuchaemost' ot vneshnikh i vnutrennikh faktorov [Relation of the effect of psychostimulants on learning ability to internal and external factors]. Biull Eksp Biol Med. 1984 Jan;97(1):53-5. Russian. PMID: 6140969. 9: CORADESCHI C, CONTINI P, ZILLI A. RISULTATI DI ALCUNE PROVE PSICOLOGICHE A SEGUITO DI SOMMINISTRAZIONE DELLA (DIETILAMMONIOETOSSICARBONIL)-3 PIRIDINA ("EUCLIDAN") [RESULTS OF SOME PSYCHOLOGICAL TESTS FOLLOWING THE ADMINISTRATION OF 2-DIETHYLAMINOETHYL NICOTINATE (EUCLIDAN)]. G Gerontol. 1963 Oct;11:949-53. Italian. PMID: 14099931. 10: Bobkov IuG, Morozov IS. Korrektsiia psikhodeprimiruiushchikh éffektov benzodiazepinovykh trankvilizatorov vvedeniem psikhoénergizatorov [Correction of psychodepressive effects of benzodiazepine tranquilizers by administration of psychostimulants]. Biull Eksp Biol Med. 1982 Oct;94(10):48-51. Russian. PMID: 6129008.